Lavesten (Fluvastatin Sodium)

Fluvastatin inhibits the enzyme HMG‑CoA reductase, which is essential for cholesterol synthesis in the liver. This inhibition reduces hepatic cholesterol production, leading to increased expression of LDL receptors on liver cells and enhanced removal of LDL cholesterol from the bloodstream.

The specific dose of Lavesten is determined by the prescribing clinician based on the individual’s cholesterol levels, overall cardiovascular risk, and other health factors. Patients should follow the dosage instructions provided by their healthcare professional.

Statins, including fluvastatin, are generally contraindicated during pregnancy and lactation because of potential risks to the fetus or infant. Use is only considered if the potential benefit justifies the possible risk, and it should be discussed with a qualified healthcare provider.

To order Lavesten, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lavesten (fluvastatin) is a moderate‑intensity statin that offers effective LDL‑cholesterol reduction with a relatively favorable safety profile. Compared with higher‑intensity statins such as atorvastatin or rosuvastatin, fluvastatin may have a lower risk of muscle‑related side effects, but the degree of cholesterol lowering may be less pronounced.

Lavesten should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date indicated on the label.

Lavesten is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

The most serious risks include rhabdomyolysis, a severe muscle breakdown that can lead to kidney failure, and significant liver injury indicated by elevated transaminases. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice.

Lavesten is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, or known hypersensitivity to fluvastatin or any excipients. It should also be avoided in pregnant or nursing women unless the benefits outweigh the risks, and caution is advised in patients with severe renal impairment.